Vepdegestrant outperforms fulvestrant in ESR1-mutant advanced breast cancer

Vepdegestrant significantly improved progression-free survival (PFS) compared with fulvestrant in advanced breast cancer participants with an oestrogen receptor 1 (ESR1) mutation. However, the benefit did not extend to the broader intention-to-treat population, where the difference in PFS was not statistically significant. Vepdegestrant is the first PROteolysis TArgeting Chimaera (PROTAC) oestrogen receptor (ER)-targeting molecule to reach clinical trial phase 3 evaluation. Dr Erika Hamilton (Sarah Cannon Research Institute, TN, USA) presented the initial findings of the phase 3 VERITAC-2 trial (NCT05654623), a multicentre study including 624 participants with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who had previously received one line of endocrine therapy plus a CDK4/6 inhibitor [1, 2]. Participants were rando...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025